CVMP opinions on veterinary medicinal products

The Committee adopted a negative opinion for a marketing authorisation for Scovella (velagliflozin), a product classified as intended for a limited market, for the treatment of hyperinsulinaemia and associated clinical signs (e.g., laminitis) in insulin-dysregulated horses and ponies not responsive to changes in husbandry and exercise regimen.

The Committee adopted a revised positive opinion for a marketing authorisation for Nobivac NXT HCPChFeLV, for active immunisation of cats to reduce mortality, clinical signs and virus excretion caused by infection with feline herpesvirus type 1 (FHV); to reduce the clinical signs and virus excretion caused by infection with feline calicivirus (FCV); to prevent mortality, clinical signs, leucopenia and virus excretion caused by infection with feline panleucopenia virus (FPL); to reduce the clinical signs and bacterial excretion caused by infection with Chlamydia felis; and to reduce…